USANew treatments and approvals
Etuvetidigene autotemcel approved as first gene therapy for Wiskott-Aldrich syndrome
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA has approved etuvetidigene autotemcel for Wiskott-Aldrich syndrome. The treatment is for patients who need a stem cell transplant but have no suitable related donor. The approval covers patients aged 6 months and older. The patient's own blood stem cells are genetically corrected and given back. In data from 27 patients, a 93% reduction in severe infections was reported. A 60% reduction in moderate-to-severe bleeding was also reported.
What does it mean for patients and families?
An option other than transplantation has emerged for patients without a suitable donor. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
FDA: FDA Approves First Gene Therapy Treatment for Wiskott-Aldrich Syndrome
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Wiskott-Aldrich syndrome
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.